Value
3.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 3.0 |
- ▸Expensive valuation
PTGX · Why this verdict
Why Protagonist Therapeutics (PTGX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Protagonist Therapeutics shows strong revenue growth of 99% year over year and a positive chart setup including a golden cross and bullish MACD, but pipeline concentration in only two assets (Icotyde and rusfertide) combined with a single partnership counterparty creates binary risk that overwhelms the bullish technical picture.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue grew 99% year over year, placing the company among the top-ranked growth names in its peer group (8.4/10 growth rank), suggesting the pipeline is generating commercial or milestone revenue ahead of expectations. Growth breakdown | Revenue grows by at least 30% year over year in each of the next 2 annual reporting periods. | →Stable |
| CounterRevenue recognition in biotech is often lumpy, reflecting milestone payments rather than recurring product sales; a single large milestone can create the appearance of 99% growth that will not repeat. | ||
The entire investment thesis rests on two assets — Icotyde and rusfertide — with development and commercialization dependent on a single counterparty, creating a scenario where a setback in either program or a disruption to the partnership could eliminate most of the company's value. Bear case | Both pipeline assets advance to the next clinical or regulatory milestone within 18 months without setback or partnership renegotiation. | →Stable |
| CounterFocused pipeline companies with a single partner often move faster to commercial milestones than diversified biotechs because all resources are aligned on a shared goal. | ||
The stock is in a golden cross configuration (50-day crossing above 200-day), trades above all moving averages, and shows a bullish MACD reading with RSI at 65, indicating positive price momentum that the market is rewarding. V9 | Price remains above the 200-day moving average for at least 6 months while RSI stays above 50. | →Stable |
| CounterThe stock has already surpassed its analyst price target, meaning even with positive technical momentum, there may be limited upside before profit-taking becomes dominant. | ||
Short interest at 13% of float and a put/call ratio of 1.82 indicate meaningful bearish positioning by informed participants, combined with implied volatility of 89% that amplifies downside risk if any negative catalyst emerges. Risk breakdown | Short interest falls below 8% within 12 months as positive pipeline news causes short covering. | →Stable |
| CounterHigh short interest in a biotech that has rallied sharply creates the conditions for a short squeeze that could drive prices well above intrinsic value in the short term. | ||
Revenue grew 99% year over year, placing the company among the top-ranked growth names in its peer group (8.4/10 growth rank), suggesting the pipeline is generating commercial or milestone revenue ahead of expectations.
→StableGrowth breakdown
- Expectation
- Revenue grows by at least 30% year over year in each of the next 2 annual reporting periods.
CounterRevenue recognition in biotech is often lumpy, reflecting milestone payments rather than recurring product sales; a single large milestone can create the appearance of 99% growth that will not repeat.
The entire investment thesis rests on two assets — Icotyde and rusfertide — with development and commercialization dependent on a single counterparty, creating a scenario where a setback in either program or a disruption to the partnership could eliminate most of the company's value.
→StableBear case
- Expectation
- Both pipeline assets advance to the next clinical or regulatory milestone within 18 months without setback or partnership renegotiation.
CounterFocused pipeline companies with a single partner often move faster to commercial milestones than diversified biotechs because all resources are aligned on a shared goal.
The stock is in a golden cross configuration (50-day crossing above 200-day), trades above all moving averages, and shows a bullish MACD reading with RSI at 65, indicating positive price momentum that the market is rewarding.
→StableV9
- Expectation
- Price remains above the 200-day moving average for at least 6 months while RSI stays above 50.
CounterThe stock has already surpassed its analyst price target, meaning even with positive technical momentum, there may be limited upside before profit-taking becomes dominant.
Short interest at 13% of float and a put/call ratio of 1.82 indicate meaningful bearish positioning by informed participants, combined with implied volatility of 89% that amplifies downside risk if any negative catalyst emerges.
→StableRisk breakdown
- Expectation
- Short interest falls below 8% within 12 months as positive pipeline news causes short covering.
CounterHigh short interest in a biotech that has rallied sharply creates the conditions for a short squeeze that could drive prices well above intrinsic value in the short term.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -105% of revenue
- ▸Rule of 40: -6 (fail)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 99% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 81)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.2 |
| Analyst rating | 8.5 |
| Price target | 4.1 |
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $22,987,332 (0.293% of mkt cap)
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.3 |
| growth rank | 8.4 |
- ▸Industry growth leader
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 10.0 |
Risk (lower is worse)
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.3 |
| days to cover | 0.0 |
| volatility | 2.8 |
| put call | 8.7 |
| implied vol | 2.5 |
| max pain risk | 3.0 |
| beta | 3.9 |
| debt equity | 4.0 |
- ▸High IV: 65%
- ▸Above max pain $60
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.2=NEGATIVE
Warning (0)
none
Reward-to-Risk
-1.20
Upside
-18.0%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.83>1.3
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-1.2=NEGATIVE.
The strongest dimensions are Growth at 10.0, Momentum at 6.6, and Sentiment at 6.4; the weakest are Value at 3.0, Quality at 3.1, and Technical at 3.4. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -1.20 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The entire investment thesis rests on two assets — Icotyde and rusfertide — with development and commercialization dependent on a single counterparty, creating a scenario where a setback in either program or a disruption to the partnership could eliminate most of the company's value.
Trip ifEither pipeline asset fails a clinical endpoint or the partnership agreement is modified to reduce milestone payments by more than 20%.
- P2Revenue grew 99% year over year, placing the company among the top-ranked growth names in its peer group (8.4/10 growth rank), suggesting the pipeline is generating commercial or milestone revenue ahead of expectations.
Trip ifRevenue growth falls below 20% year over year in any single annual reporting period.
- P3The stock is in a golden cross configuration (50-day crossing above 200-day), trades above all moving averages, and shows a bullish MACD reading with RSI at 65, indicating positive price momentum that the market is rewarding.
Trip ifPrice falls below the 200-day moving average and RSI drops below 40 within 30 days.
- P4Short interest at 13% of float and a put/call ratio of 1.82 indicate meaningful bearish positioning by informed participants, combined with implied volatility of 89% that amplifies downside risk if any negative catalyst emerges.
Trip ifShort interest rises above 18% of float for more than 60 consecutive days.